

314, T. V. Indusstrial Estate, S.K. Ahire Marg, Worli, Mumbai - 400 030. India

> Tel.:+91 22 6663 5456 Fax:+91 22 6663 5460

E-mail: auro@aurolabs.com Web: www.aurolabs.com

Reg. Off. / Mfg. Unit: K-56, M. I. D. C. Tarapur, Dist. Palghar, Maharashtra - 401506.

CIN No. L33125MH1989PLC051910

Date: November 1, 2018

To BSE Limited, Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Reg: Security Code No. 530233

Sub: Outcome of the Board Meeting dated November 1, 2018.

Dear Sir,

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors at their Meeting held today (i.e. Thursday, November 1, 2018), has approved the Unaudited Financial Results for the Quarter / Half year ended September 30, 2018 as recommended by the Audit Committee alongwith the statement of Assets and Liabilities and Limited Review Report by the Statutory Auditors of the Company.

In this regard, we are enclosing herewith:

- Unaudited Financial Results for the Quarter/Half year ended September 30, 2018.
- Limited Review Report received from the Statutory Auditor of the Company.
- > Statement of Assets & Liabilities as on September 30, 2018.

The Meeting of the Board commenced at 2.35 P. M. and concluded at 3.20 P. M. The results will be published in the newspaper pursuant to Regulation 47(1)(b) of SEBI (LODR) Regulations, 2015 in due course.

Kindly take the same on record and acknowledge.

Thanking You,

Yours Faithfully,

FOR ACKR LABORATORIES LIMITED

SHARAT DEORAH CHAIRMAN & MANAGING DIRECTOR

DIN: 00230784 Encl.: as above


AURO LABORATORIES LIMITED CIN NO. :- L33125MH1989PLC051910

Regd. Office: K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR BOISAR, DIST. PALGHAR 401506, MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

ANNEXURE - I

MAR	(T - I		-				Rs. In La
	STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE Q	UARTER AND	HALF YEARE EN		MBER 2018	of Decorphic Section	
		3 Months ended	Preceding 3 Months ended	Corresponsing 3 Months ended in the Previous Year	- Half year Ended		Previous Year Ended
Sr.	\$0 \$\dot \text{ADMAC}(\overline{\ove	30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations	100 TE		2 2023 2 2402333			Sac
	(a) Net Sales/Income from Operations (Net of excise duty)	1254.91	1,046.78	971,79	2,301.69	1,724.25	4,079.40
2	Other Income	26.11	3.09	13.76	29.20	16,40	51.39
3	Total Revenue (1 + 2)	1,281.02	1,049.87	985.55	2,330.89	1,740.65	4,130.79
4	Expenses	121 5				***	
5.00	a. Consumption of raw material	882.56	716.41	634.72	1,598.97	1,214.07	2,461.65
	b. Purchase of Stock-in-trade	002.00	1.04	0.85	1.04	0.85	2,401.6
	c. (Increase) / decrease in Finished Goods stock	(40.41)	(65.90)	9.15	(106.31)	1-1-1-1	-
	in trade and work in progress	(10.01)	(65.56)	3,10	(100.51)	(112.02)	0.2
	d. Employee benefits expense	91.43	86.65	56.74	178.08	129.06	369.5
r.241500c	e. Finance Cost	18.84	22.80	32.93	41.64	62.82	108.8
SANGE AS	f. Depreciation and amortisation expenses	26.00		23.00	50.50	45.00	93.1
	g. Other Expenses	196.14	179.61	139.92	375.75	268.23	614.6
	Total Expenses (4)	1,174.56	965.11	897.31	2,139.67	1,608.01	3,658.09
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)	106.46	84.76	88.24	191.22	132.64	472.74
6	Exceptional items				3.5	-	_
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)	106.46	84.76	88.24	191.22	132.64	472.74
8	Extraordinary items	(*)	F. 1	*	-	-	
9	Profit / (Loss) before tax (7 ± 8)	106.46	84.76	88.24	191.22	132.64	472.74
10	Tax expense		-	-	-	9	(74)
63500	(a) Current tax expesnes for current year	26.62	21.19		47.80		127.34
	(b) MAT credit (where applicable)						# # \$
	(c) Defferered tax	-		. Salana) /		(7.5€
11	Profit / (Loss) for the period from continuing operation (9± 10)	79.84	63.57	88.24	143.42	132.64	352.96
12	Profit / (Loss) for discontinuing operations	1600	a series a	9.003004 E3 V4		2	140
13	Tax expense of discontinuing operations	1993	- 1	4 6			020
14	Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)	79.84	63.57	88.24	143.42	132.64	352,96
15	Other Comprehensive Income	17.16	17.92	(5.74)	17.16	3.69	4.63
16	Total Comprehensive Income for the period (14 ± 15)	97.00	81.49	82.50	160.58	136.33	357.59
17	Paid-up equity share capital	623.25	623.25	623.25	623.25	623.25	623,25
	(Face value of Rs. 10 each)	5.1030		-0 (A)(100) A)	100000 W		
17	Reserves excluding Revaluation Reserves as	-	200000000000000000000000000000000000000	ā 5Ē	\$ \$48.000 \$.	5. COMPANY N.	674.52
18	per balance sheet of previous accounting year) Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):	estimistrii III				0 000	
10	(a) Basic	1.28	1.02	1.42	2.30	2.13	5.66
	(b) Diluted	1.28	1.02	1.42	2.30	2.13	5.66



<u>Auro Laboratories Limite</u>	<u>d</u>				
Statement of Assets and Laibilities (Ind AS)					
		(Rs. In Laki			
Particulars	As at	As at			
	30.09.2018	31.03.2018			
	Unaudited	Audited			
AASSETS					
L 11 a					
1. Non-Current Assets	1				
(a) Property, Plant and Equipment	1,316.74	1302.3			
(b) Capital Work -in-Progress	186.11	107.2			
(c) Investment Property	i - 1	-			
(d) Financial Assets	1				
(i) Investments	4.88	4.8			
(ii) Loans	-	_			
(iii) Others	-	-			
(e) Other non-current assets - Capital Advance	-	-			
2. Current assets					
(c) Inventories	285.42	149.1			
(b) Financial Assets	203.42	149.1			
(i) Investments	I				
(ii) Trade Reveivables	1 102 08	007			
(iii) Cash and cash equivalents	1,102.06	837.4			
(iv) Bank balances other than (iii) above	138.14	179.7			
(v) Loans	74.01	45.2			
(vi) Others	1				
(c) Other Current Assets	250.20	414.2			
TOTAL ASSETS	0057.50				
TOTAL ASSETS	3357.56	3040.3			
EQUITY AND LIABILITIES					
1. Equity					
(a) Equity Share Capital	623.25	623.2			
(b) Other Equity	835.10	674.5			
***	555.10	074.0			
2. Liabilities					
(I) Non-Current Liabilities					
(a) Financial Liabilities	620.33	617.8			
(i) Other Financial Liabilities	218.75	302.0			
(b) Provisions	210.73	302.0			
(c) Deferred Tax Liabilities (Net)	144.41	144.4			
] ''	; ~ ,4			
(II) Current Liabilities					
(a) Financial Liabilities					
(i) Trade Payables	786.76	530.1			
(b) Other Current Liabilities	59.35	73.2			
(c) Provisions	59.55 69.61	73.2 74.9			
1	09.61	74.9			
	2227	3040.3			
(d) Current Tax Liabilities (net) TOTAL EQUITY AND LIABILITIES otes:	3357.56	30			

Notes:

 The above unaudtied financial results for the quarter ended 30th September, 2018 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 1st November 2018.

 The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.

Limited review has been carried out by the Statutory Auditors of the Company.

FOR & BEHALF OF BOARD OF DIRECTORS

SHARAT DEORAH

CHAIRMAN & MANAGING DIRECTOR.

DIN NO. 00230784

Place : Mumbai Date : 01.11.2018



To,
The Board of Directors,
Auro Laboratories Limited.

We have reviewed the standalone Ind AS financial results of Auro Laboratories Ltd. ("the company") for the quarter ended September 30, 2018, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.

This Statement is the responsibility of the Company's Management and had been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether thefinancial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than anaudit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements prepared in accordance with generally accepted accounting standards in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05,2016 and "CIR/IMD/DF1/69/2016" dated August 10,2016, including the manner in which it is to be disclosed or that it contains any material misstatement.

For Khurdia Jain&Co.

Chartered Accountants

SampatKhurdia

Partner

Membership No.33615 Firm Reg. No. 120263W

Place: Mumbai Date: 01/11/2018